While most existing research has focused on HSP90AA1 and its activators like AHSA1 or inhibitors like CDC37, revealing important mechanisms by which HSP90AA1 and interacting proteins such as HSP70 maintain cellular homeostasis and proliferative activity under stress [20–23], the resultant HSP90AA1 inhibitor drugs have offered new hope for the treatment of various cancers, including lung cancer, especially after the onset of drug resistance [24, 25]. Here, CDC37 is linked to cancer.